Bristol Myers Squibb stock heads into pipeline catalyst week

Bristol Myers Squibb is entering November with its late-stage pipeline in focus after the company reported positive Phase 3 results for admilparant in idiopathic pulmonary fibrosis on October 12. The update supports the drug's potential as a first-in-class treatment, while the company prepares for regulatory discussions and additional clinical readouts.

In the ALOFT-IPF trial, the 60-milligram dose delivered a statistically significant improvement in the change in forced vital capacity from baseline to Week 52 compared with placebo. The 120-milligram dose slowed the decline in lung function, but the difference was not statistically significant. Bristol Myers Squibb said discontinuations caused by adverse events were low and similar to placebo across the treatment arms.

The study enrolled approximately 1,255 adults with idiopathic pulmonary fibrosis and tested both doses twice daily against placebo. Admilparant is an oral, selective lysophosphatidic acid receptor 1 antagonist. Bristol Myers Squibb plans to complete its data evaluation and engage with health authorities on potential regulatory submissions. Topline results from the fully enrolled ALOFT-PPF trial in progressive pulmonary fibrosis are expected in early 2027, according to the company's October 12 announcement.

Late-Stage Pipeline In Focus

On the October 29 earnings call, management described the ALOFT-IPF result as one of several positive registrational readouts in 2026. Executives also cited interim Phase 3 results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and positive results for the CAR-T candidate arlo-cel. The company is engaging with the FDA on next steps for RYZ101.

Further catalysts include Phase 3 data for milvexian in secondary stroke prevention and Sotyktu in lupus before year-end. Bristol Myers Squibb also plans to present open-label data from the ADEPT-1 and ADEPT-3 studies of Cobenfy in Alzheimer's disease psychosis at the Clinical Trials on Alzheimer's Disease conference in November. The earnings-call transcript records management's expectations for these events.

Bristol Myers Squibb stock traded at 55.43 euros on Lang & Schwarz at 10:18 CET on Monday, November 2, 2026. The real-time quote of Bristol Myers Squibb stock provides the latest trading view.

The company's third-quarter earnings call also highlighted execution in the growth portfolio and continued investment in manufacturing capacity. For investors, the opportunity rests on turning clinical wins into approvals and launches while managing development, regulatory and patent risks.

The S&P 500 provides the broader market context for U.S. equities: Current market reports.

For further company updates, see More news and analyses on Bristol Myers Squibb stock.